Skip to main content Skip to search Skip to main navigation

Switzerland, EU-MDR und a missing MRA

The new European medical device regulation came into force on 26 May 2021. Parallel, a complete revision of the Medical Devices Regulation MepV was carried out in Switzerland, under the responsibility of the Swiss BAG (Federal Office of Public Health). In context of the alignment of the MepV and the KlinV-Mep with the new EU regulations MDR and IVDR on medical devices, it was also necessary to update the existing MRA (Mutual Recognition Agreement) between Switzerland and the EU. This agreement ensures barrier-free market access and joint implementation. The MRA is, in turn, part of an "overall package" of an institutional framework agreement (Insta), which has not yet been conclusively agreed on. On the contrary: Switzerland has meanwhile broken off negotiations with the EU and described them as "having failed".

This scenario has serious consequences:

Mutual market access and movement of good of medical devices, coordinated market surveillance activies and exchange of information between authorities or mutual recognition of certificates of conformity are affected by the pending update of the MRA agreement. Without an MRA update, Swissmedic will be denied access by the authorities to the central European database for medical devices (EUDAMED), which has been available since 1 December 2020. Swissmedic will be excluded from the working groups on the joint surveillance of new medical products and will not be able to access enforcement-relevant data.

What comes next?  

In preparation for a failed agreement, the Swiss Federal Council passed an amending decree to the MepV on 19 May 2021, to supplement the revised medical law. This defines varius measures and transitional periods to guarantee the supply of safe devices in Switzerland and to dampen the negative effects on market surveillance.The provisions allow, e.g., unilateral market acces for medical devices certified in the EU according to the new regulation and thus reduce supply disruptions in Switzerland. Since 26 May 2021, Swiss manufacturers must establish a socalled authorised representative for their products in the EU.

The Federal Council has set longer transition periods in some cases. These relate in particular to registration and notification obligations. Manufacturers, importers and authorised representatives must register with Swissmedic and receive a unique identification number (CHRN). This registration for a CHRN has already been prepared in advance.

Thus, there is hope that an agreement between Switzerland and the EU can still be achieved.


Source:

BAG Switzerland: News room

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

IPEC: Stability Guide for Excipients has been Updated

IPEC: Stability Guide for Excipients has been Updated

The IPEC Stability Guide for Pharmaceutical Excipients has been updated and is now available as version 3 (2026), as announced on the IPEC (International Pharmaceutical Excipients Council) website.

Read more
EU: “Forever Chemicals” in a Conflict of Interests

EU: “Forever Chemicals” in a Conflict of Interests

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

Read more
Handover of Computerised Systems to the Operating Department

Handover of Computerised Systems to the Operating Department

The GMP-compliant handover of computerised systems to operations is a critical step in the Computer System Validation (CSV) lifecycle. Beyond go-live and hypercare, clearly defined responsibilities, comprehensive documentation and well-trained personnel are essential to maintaining a validated state throughout routine operation.
Read more
How is the Effectiveness of CAPAs Verified?

How is the Effectiveness of CAPAs Verified?

Here's the answer:
Read more
APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

The Active Pharmaceutical Ingredients Committee (APIC) has published Version 3 of the document “GDP for APIs: How to Do” (June 2026) on its website. The document provides practical guidance on implementing Good Distribution Practice for active pharmaceutical ingredients.

Read more
TGA: Seeks Feedback on Planned Adoption of 11 International Scientific Guidelines

TGA: Seeks Feedback on Planned Adoption of 11 International Scientific Guidelines

Australia's regulatory authority, the TGA (Therapeutic Goods Administration), pursues a strategy of aligning its regulatory approaches as closely as possible with comparable international standards. These include the regulatory requirements of the EU, the FDA and the ICH. In this context, around 370 international scientific guidelines have already been adopted.

Read more
Previous
Next